Qiagen N.V. $QGEN Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Qiagen N.V. (NYSE:QGEN) by 18.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,334,083 shares of the company’s stock after acquiring an additional 360,153 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Qiagen were worth $103,372,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. MAI Capital Management grew its stake in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after buying an additional 796 shares during the period. GAMMA Investing LLC boosted its stake in Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after acquiring an additional 980 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Qiagen by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after purchasing an additional 1,183 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

QGEN has been the topic of several analyst reports. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and lowered their target price for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Barclays reiterated an “overweight” rating and issued a $57.89 price objective (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Finally, Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Two analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $52.84.

Qiagen Stock Up 16.3%

QGEN stock opened at $55.35 on Wednesday. The company has a 50 day moving average of $48.39 and a two-hundred day moving average of $49.41. Qiagen N.V. has a 12-month low of $39.61 and a 12-month high of $57.81. The company has a market cap of $11.69 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 2.19 and a beta of 0.66. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. The firm had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. On average, equities analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.